Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0917798 (cerebral ischemia)
 17,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

G-CSF is a potent hematopoietic factor that enhances survival and drives differentiation of myeloid lineage cells, resulting in the generation of neutrophilic granulocytes. Here, we show that G-CSF passes the intact blood-brain barrier and reduces infarct volume in 2 different rat models of acute stroke. G-CSF displays strong anti-apoptotic activity in mature neurons and activates multiple cell survival pathways. Both G-CSF and its receptor are widely expressed by neurons in the CNS, and their expression is induced by ischemia, which suggests an autocrine protective signaling mechanism. Surprisingly, the G-CSF receptor was also expressed by adult neural stem cells, and G-CSF induced neuronal differentiation in vitro. G-CSF markedly improved long-term behavioral outcome after cortical ischemia, while stimulating neural progenitor response in vivo, providing a link to functional recovery. Thus, G-CSF is an endogenous ligand in the CNS that has a dual activity beneficial both in counteracting acute neuronal degeneration and contributing to long-term plasticity after cerebral ischemia. We therefore propose G-CSF as a potential new drug for stroke and neurodegenerative diseases.
 ...
PMID:The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. 1600 67

Granulocyte-colony stimulating factor (G-CSF) receptor signaling counteracts detrimental pathways in ischemic stroke. In rodents, neuroprotection provided by the G-CSF system involves up-regulation of the G-CSF receptor and its ligand, G-CSF, during cerebral ischemia. The confirmation of a similar response in the human brain would be an important rationale for the use of G-CSF in clinical stroke trials. Therefore, the temporal and cellular profile of G-CSF and G-CSF receptor expression was examined in a series of human stroke brains. The median age of the 21 stroke patients was 67 years; median time from death to autopsy was 24 h (range: 10-67 h). In acute ischemic stroke, strong neuronal G-CSF receptor immunoreactivity was encountered in the infarct area and the peri-infarct rim as compared to the contralateral cortex. In subacute infarctions, microglial and macrophage G-CSF receptor immunoreactivity predominated, whereas chronic infarction was characterized by the presence of G-CSF receptor expressing reactive astrocytes. Neuronal G-CSF expression was encountered very early upon ischemic stroke. At later time-points, an up-regulation of vascular G-CSF expression in the peri-infarct area prevailed. In conclusion, the observed up-regulation of G-CSF receptors and G-CSF points towards a role in the pathophysiology of human ischemic stroke.
 ...
PMID:Granulocyte-colony stimulating factor (G-CSF) and G-CSF receptor expression in human ischemic stroke. 1704 71

Incidence of cerebral vascular disease (CVD) is higher in patients with diabetes mellitus (DM) than that in individuals without DM, and neuronal apoptosis determines the severity of cerebral infarction. However, there is no effective therapy for CVD. Granulocyte-colony stimulating factor (G-CSF), a potent hematopoietic factor, could inhibit apoptosis of hematopoietic progenitor cells. However, its effect on neuronal cells is still unclear. In this study, we investigated the anti-apoptosis properties of G-CSF in neurons following focal cerebral ischemia in diabetic rats. The diabetic condition was generated in rats by intravenous injection of streptozotocin. After 6 weeks, diabetic rats underwent middle cerebral artery occlusion (MCAO) and received subcutaneous administration of G-CSF (50 microg/kg) daily for 7, 14 or 21 days. We analyzed the changes in neurological severity scores, infarct volume, number of apoptotic neurons, and the expression of G-CSF receptor, phosphorylated signal transducer and activator of transcription 3 (pSTAT3), cellular inhibitor of apoptosis protein 2 (cIAP2), Bcl-2, and Bax in the brain tissue. Bax is a pro-apoptotic member of the Bcl-2 protein family. The DM rats treated with G-CSF not only showed the reduced infarct volume and decreased apoptosis cell number, but also presented improved neurological scores. The G-CSF also increased the expression of pSTAT3, Bcl-2, and cIAP2 proteins as well as Bcl-2 mRNA, but inhibited Bax protein expression in the brain. These results indicate that G-CSF partially increases neuronal survival by affecting apoptosis pathways. G-CSF provides a potential treatment for stroke and other neurological dysfunction accompanied by neuronal apoptosis.
 ...
PMID:Granulocyte-colony stimulating factor inhibits neuronal apoptosis in a rat model of diabetic cerebral ischemia. 1883 93